Guangzhou Gillion Biotherapeutics

Gillion Biotherapeutics is a clinical-stage biotechnology company based in Guangzhou, China, focused on developing functional cures for chronic hepatitis B (CHB). The company utilizes its proprietary G-cure platform to develop nucleic acid-based therapeutics, specifically small interfering RNA (siRNA) molecules designed to silence viral gene expression. Its lead candidate, GLN-001, is currently in Phase 1 clinical trials and aims to significantly reduce HBsAg levels to restore the host immune response. Gillion is strategically positioned to address the high prevalence of HBV in the Asia-Pacific region and globally. The company is backed by CARsgen Therapeutics and leverages advanced molecular biology to target viral reservoirs.